Ipsen Announces Encouraging Phase II Results for IPN10200 in Treating Glabellar Lines, Demonstrating Sustained Effectiveness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 22 2025
0mins
Should l Buy ?
Source: NASDAQ.COM
Phase II LANTIC Trial Results: Ipsen's IPN10200 showed significant improvement in treating glabellar lines at Week 4 compared to placebo, with continued superior results at Week 36 versus Dysport.
Future Developments: Data from the trial will be presented at a scientific conference in 2026, and Phase III activities have begun, while Phase II continues for other therapeutic uses like spasticity and migraines.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
